Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4405441 | 0.74 | CNR2 (0.52) | MGLLFAAHALDH1A1DAGLATRPV1 | |
| SCHEMBL15038853 | 0.69 | MGLL (0.48) | MGLLFAAHALDH1A1DAGLATRPV1 | |
| SCHEMBL2183633 | 0.69 | MGLL (0.85) | MGLLFAAHALDH1A1DAGLATRPV1 | |
| SCHEMBL28017015 | 0.67 | ALDH1A1 (0.44) | MGLLFAAHALDH1A1DAGLATRPV1 | |
| SCHEMBL9643255 | 0.66 | MGLL (0.59) | MGLLFAAHALDH1A1DAGLATRPV1 | |
| SCHEMBL11335075 | 0.64 | CYP19A1 (0.50) | MGLLFAAHKCNA5 | |
| SCHEMBL2092704 | 0.64 | CNR2 (0.54) | MGLLFAAHALDH1A1DAGLATRPV1 | |
| SCHEMBL4409159 | 0.64 | CNR2 (0.83) | MGLLFAAHALDH1A1DAGLATRPV1 | |
| SCHEMBL96013 | 0.64 | FAAH (0.39) | MGLLFAAHALDH1A1DAGLATRPV1 | |
| SCHEMBL18496450 | 0.64 | LMNA (0.42) | MGLLALDH1A1GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | claimed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | claimed |
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | TFAM, CYP11B2, CYP11B1 | MGLL 3162/4885FAAH 2701/4885ALDH1A1 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.